Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in Indian Patients With Progressive mCRPC Previously Treated With Docetaxel
NCT03641560Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2018
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Primary endpoint: Treatment-Emergent Adverse Events up to 1899 days. Started Sep 2018; status: completed.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03641560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03641560.